Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05878288 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Study acronym: DISCERN
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 30 words
    • Secondary endpoints: details revised at 2 of 6 entries
  2. Enrollment target: estimated 10 to confirmed 11v4
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2023 to May 26, 2023
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.
Trial Details
NCT Number NCT05878288
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: University of Melbourne, University of Adelaide, Monash University, Regeneron Pharmaceuticals, Sanofi
Conditions
(from sponsor)		 Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin Cancer
Related terms Neoplasms
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov